HomepageMedicineFDA Approves Sanofi’s Rapid Acting Insulin Biosimilar Merilog for Diabetes Medicine FDA Approves Sanofi’s Rapid Acting Insulin Biosimilar Merilog for Diabetes admin Posted on February 18, 2025 Meilog marks the first rapid-acting insulin biosimilar to gain FDA approval for the treatment of diabetes. LEAVE A RESPONSE Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website Save my name, email, and website in this browser for the next time I comment. admin View all posts Post navigation Previous PostArvind SmartSpaces sign ₹600-cr real estate deal in Ahmedabad Next PostXi Jinping's educational philosophy now in four new languages You Might Also Like Medicine The Twists and Turns in Biopharma Dealmaking: 2024 Trends admin January 29, 2024 Medicine Relyvrio Falls Short of Primary Endpoint in Phase III PHOENIX Trial in Patients with ALS admin March 9, 2024 Medicine Pharma Pulse 5/3/24: Wegovy Sales More Than Double, The Effects of the IRA & more admin May 5, 2024 Medicine Evolution Optiks Receives FDA 510(k) Clearance for LFR-260 as the First Light Field Powered Subjective Tele-Fractor admin June 8, 2024
Medicine Relyvrio Falls Short of Primary Endpoint in Phase III PHOENIX Trial in Patients with ALS admin March 9, 2024
Medicine Pharma Pulse 5/3/24: Wegovy Sales More Than Double, The Effects of the IRA & more admin May 5, 2024
Medicine Evolution Optiks Receives FDA 510(k) Clearance for LFR-260 as the First Light Field Powered Subjective Tele-Fractor admin June 8, 2024